Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2001 1
2002 1
2004 1
2005 2
2006 6
2007 5
2008 8
2009 10
2010 7
2011 4
2012 6
2013 5
2014 11
2015 12
2016 9
2017 9
2018 18
2019 8
2020 15
2021 10
2022 6
2023 11
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

151 results

Results by year

Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
Page 1
Showing results for M. T. parida
Your search for M. T. Paridah retrieved no results
Distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell lymphoma.
Haradhvala NJ, Leick MB, Maurer K, Gohil SH, Larson RC, Yao N, Gallagher KME, Katsis K, Frigault MJ, Southard J, Li S, Kann MC, Silva H, Jan M, Rhrissorrakrai K, Utro F, Levovitz C, Jacobs RA, Slowik K, Danysh BP, Livak KJ, Parida L, Ferry J, Jacobson C, Wu CJ, Getz G, Maus MV. Haradhvala NJ, et al. Nat Med. 2022 Sep;28(9):1848-1859. doi: 10.1038/s41591-022-01959-0. Epub 2022 Sep 12. Nat Med. 2022. PMID: 36097221 Free PMC article.
Chimeric antigen receptor (CAR)-T cell therapy has revolutionized the treatment of hematologic malignancies. ...Our analyses reveal the temporal dynamics of effective responses to CAR-T therapy, the distinct molecular phenotypes of CAR-T cells with differing …
Chimeric antigen receptor (CAR)-T cell therapy has revolutionized the treatment of hematologic malignancies. ...Our analyses reveal t …
Cell Competition Shapes Metastatic Latency and Relapse.
Kim K, Huang H, Parida PK, He L, Marquez-Palencia M, Reese TC, Kapur P, Brugarolas J, Brekken RA, Malladi S. Kim K, et al. Cancer Discov. 2023 Jan 9;13(1):85-97. doi: 10.1158/2159-8290.CD-22-0236. Cancer Discov. 2023. PMID: 36098678 Free PMC article.
Using cancer metastatic latency models, we show that cell competition results in the displacement of latent metastatic (Lat-M) cells from the primary tumor. Lat-M cells resist anoikis and survive as residual metastatic disease. ...Thus, an unexpected consequence of …
Using cancer metastatic latency models, we show that cell competition results in the displacement of latent metastatic (Lat-M) cells …
T cell receptor repertoires associated with control and disease progression following Mycobacterium tuberculosis infection.
Musvosvi M, Huang H, Wang C, Xia Q, Rozot V, Krishnan A, Acs P, Cheruku A, Obermoser G, Leslie A, Behar SM, Hanekom WA, Bilek N, Fisher M, Kaufmann SHE, Walzl G, Hatherill M, Davis MM, Scriba TJ; Adolescent Cohort Study team; GC6-74 Consortium. Musvosvi M, et al. Nat Med. 2023 Jan;29(1):258-269. doi: 10.1038/s41591-022-02110-9. Epub 2023 Jan 5. Nat Med. 2023. PMID: 36604540 Free PMC article.
In the present study, we used single-cell and bulk T cell receptor (TCR) sequencing and the GLIPH2 algorithm to analyze M. tuberculosis-specific sequences in two longitudinal cohorts, comprising 166 individuals with M. tuberculosis infection who progressed to …
In the present study, we used single-cell and bulk T cell receptor (TCR) sequencing and the GLIPH2 algorithm to analyze M. tub …
Evolutionary history of transformation from chronic lymphocytic leukemia to Richter syndrome.
Parry EM, Leshchiner I, Guièze R, Johnson C, Tausch E, Parikh SA, Lemvigh C, Broséus J, Hergalant S, Messer C, Utro F, Levovitz C, Rhrissorrakrai K, Li L, Rosebrock D, Yin S, Deng S, Slowik K, Jacobs R, Huang T, Li S, Fell G, Redd R, Lin Z, Knisbacher BA, Livitz D, Schneider C, Ruthen N, Elagina L, Taylor-Weiner A, Persaud B, Martinez A, Fernandes SM, Purroy N, Anandappa AJ, Ma J, Hess J, Rassenti LZ, Kipps TJ, Jain N, Wierda W, Cymbalista F, Feugier P, Kay NE, Livak KJ, Danysh BP, Stewart C, Neuberg D, Davids MS, Brown JR, Parida L, Stilgenbauer S, Getz G, Wu CJ. Parry EM, et al. Nat Med. 2023 Jan;29(1):158-169. doi: 10.1038/s41591-022-02113-6. Epub 2023 Jan 9. Nat Med. 2023. PMID: 36624313 Free PMC article.
Latent human herpesvirus 6 is reactivated in CAR T cells.
Lareau CA, Yin Y, Maurer K, Sandor KD, Daniel B, Yagnik G, Peña J, Crawford JC, Spanjaart AM, Gutierrez JC, Haradhvala NJ, Riberdy JM, Abay T, Stickels RR, Verboon JM, Liu V, Buquicchio FA, Wang F, Southard J, Song R, Li W, Shrestha A, Parida L, Getz G, Maus MV, Li S, Moore A, Roberts ZJ, Ludwig LS, Talleur AC, Thomas PG, Dehghani H, Pertel T, Kundaje A, Gottschalk S, Roth TL, Kersten MJ, Wu CJ, Majzner RG, Satpathy AT. Lareau CA, et al. Nature. 2023 Nov;623(7987):608-615. doi: 10.1038/s41586-023-06704-2. Epub 2023 Nov 8. Nature. 2023. PMID: 37938768 Free PMC article.
For example, we lack a comprehensive understanding of the mechanisms of toxicities observed in patients receiving T cell therapies, including recent reports of encephalitis caused by reactivation of human herpesvirus 6 (HHV-6)(1). Here, through petabase-scale viral genomic …
For example, we lack a comprehensive understanding of the mechanisms of toxicities observed in patients receiving T cell therapies, i …
Metabolic diversity within breast cancer brain-tropic cells determines metastatic fitness.
Parida PK, Marquez-Palencia M, Nair V, Kaushik AK, Kim K, Sudderth J, Quesada-Diaz E, Cajigas A, Vemireddy V, Gonzalez-Ericsson PI, Sanders ME, Mobley BC, Huffman K, Sahoo S, Alluri P, Lewis C, Peng Y, Bachoo RM, Arteaga CL, Hanker AB, DeBerardinis RJ, Malladi S. Parida PK, et al. Cell Metab. 2022 Jan 4;34(1):90-105.e7. doi: 10.1016/j.cmet.2021.12.001. Cell Metab. 2022. PMID: 34986341 Free PMC article.
Attenuating lactate metabolism in S-BM impedes metastasis, while M-BM adapt and survive as residual disease. In contrast to S-BM, Lat and M-BM survive in equilibrium with innate immunosurveillance, oxidize glutamine, and maintain cellular redox homeostasis through t …
Attenuating lactate metabolism in S-BM impedes metastasis, while M-BM adapt and survive as residual disease. In contrast to S-BM, Lat …
The Lipogenic Regulator SREBP2 Induces Transferrin in Circulating Melanoma Cells and Suppresses Ferroptosis.
Hong X, Roh W, Sullivan RJ, Wong KHK, Wittner BS, Guo H, Dubash TD, Sade-Feldman M, Wesley B, Horwitz E, Boland GM, Marvin DL, Bonesteel T, Lu C, Aguet F, Burr R, Freeman SS, Parida L, Calhoun K, Jewett MK, Nieman LT, Hacohen N, Näär AM, Ting DT, Toner M, Stott SL, Getz G, Maheswaran S, Haber DA. Hong X, et al. Cancer Discov. 2021 Mar;11(3):678-695. doi: 10.1158/2159-8290.CD-19-1500. Epub 2020 Nov 17. Cancer Discov. 2021. PMID: 33203734 Free PMC article.
Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance.
Naeem A, Utro F, Wang Q, Cha J, Vihinen M, Martindale S, Zhou Y, Ren Y, Tyekucheva S, Kim AS, Fernandes SM, Saksena G, Rhrissorrakrai K, Levovitz C, Danysh BP, Slowik K, Jacobs RA, Davids MS, Lederer JA, Zain R, Smith CIE, Leshchiner I, Parida L, Getz G, Brown JR. Naeem A, et al. Blood Adv. 2023 May 9;7(9):1929-1943. doi: 10.1182/bloodadvances.2022008447. Blood Adv. 2023. PMID: 36287227 Free PMC article.
A blood RNA signature for tuberculosis disease risk: a prospective cohort study.
Zak DE, Penn-Nicholson A, Scriba TJ, Thompson E, Suliman S, Amon LM, Mahomed H, Erasmus M, Whatney W, Hussey GD, Abrahams D, Kafaar F, Hawkridge T, Verver S, Hughes EJ, Ota M, Sutherland J, Howe R, Dockrell HM, Boom WH, Thiel B, Ottenhoff THM, Mayanja-Kizza H, Crampin AC, Downing K, Hatherill M, Valvo J, Shankar S, Parida SK, Kaufmann SHE, Walzl G, Aderem A, Hanekom WA; ACS and GC6-74 cohort study groups. Zak DE, et al. Lancet. 2016 Jun 4;387(10035):2312-2322. doi: 10.1016/S0140-6736(15)01316-1. Epub 2016 Mar 24. Lancet. 2016. PMID: 27017310 Free PMC article.
METHODS: In this prospective cohort study, we followed up healthy, South African adolescents aged 12-18 years from the adolescent cohort study (ACS) who were infected with M tuberculosis for 2 years. We collected blood samples from study participants every 6 months and mon …
METHODS: In this prospective cohort study, we followed up healthy, South African adolescents aged 12-18 years from the adolescent cohort stu …
Construction of M-BiVO(4)/T-BiVO(4) isotype heterojunction for enhanced photocatalytic degradation of Norfloxacine and Oxygen evolution reaction.
Baral B, Reddy KH, Parida KM. Baral B, et al. J Colloid Interface Sci. 2019 Oct 15;554:278-295. doi: 10.1016/j.jcis.2019.07.007. Epub 2019 Jul 4. J Colloid Interface Sci. 2019. PMID: 31302366
The FESEM image of MT-BiVO(4) photodeposited by Au and MnOx particles was provided strong evidence for the spatial separation of photogenerated charge carriers between M and T phase of BiVO(4) in an isotype heterojunction. The interfacing of T-BiVO(4) with …
The FESEM image of MT-BiVO(4) photodeposited by Au and MnOx particles was provided strong evidence for the spatial separation of photogenera …
151 results